A Multicenter, open-label, uncontrolled, 52-week long-term study in patients with secondary hyperparathyroidism on hemodialysis
Phase of Trial: Phase III
Latest Information Update: 07 Nov 2016
At a glance
- Drugs Etelcalcetide (Primary)
- Indications Secondary hyperparathyroidism
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
- 15 Jul 2016 Status changed from active, no longer recruiting to completed.
- 16 Jun 2016 New trial record
- 23 Apr 2015 Status changed from recruiting to active, no longer recruiting.